Home » Stocks » FLDM

Fluidigm Corporation (FLDM)

Stock Price: $7.10 USD 0.75 (11.81%)
Updated Jul 28, 2021 4:00 PM EDT - Market closed
Market Cap 525.49M
Revenue (ttm) 143.32M
Net Income (ttm) -55.86M
Shares Out 74.71M
EPS (ttm) -0.76
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 28
Last Price $7.10
Previous Close $6.35
Change ($) 0.75
Change (%) 11.81%
Day's Open 6.75
Day's Range 6.75 - 7.22
Day's Volume 3,312,167
52-Week Range 3.71 - 12.45

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Fluidigm Corp (NASDAQ: FLDM) stock is trading higher in the premarket on a report that the Company is considering a sale. According to a Bloomberg report, the medical technology firm is working with an ...

21 hours ago - Benzinga

SOUTH SAN FRANCISCO, Calif., July 08, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health i...

2 weeks ago - GlobeNewsWire

A New Platform to Simplify Deep Profiling of the Human Immune System A New Platform to Simplify Deep Profiling of the Human Immune System

2 months ago - GlobeNewsWire

FLAMIN-GO Project Seeks to Develop Organ-on-a-Chip Technology for Clinical Trials in Rheumatoid Arthritis Therapy FLAMIN-GO Project Seeks to Develop Organ-on-a-Chip Technology for Clinical Trials in Rhe...

2 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., May 14, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health in...

2 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health in...

2 months ago - GlobeNewsWire

Shares of Fluidigm (NASDAQ:FLDM) decreased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share fell 15.38% year over year to ($0.15), which missed the est...

2 months ago - Benzinga

Study Suggests Mass Cytometry Is a Valuable Tool for Predicting Individual Patient Response to Therapies Study Suggests Mass Cytometry Is a Valuable Tool for Predicting Individual Patient Response to Th...

2 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health ...

3 months ago - GlobeNewsWire

Innovation is risky, and these companies are all in.

Other stocks mentioned: GH, NNOX
4 months ago - The Motley Fool

The FDA has granted Emergency Use (EUA) approval for Fluidigm Corporation's (NASDAQ: FLDM) AZOVA COVID-19 test collection kit for use with the company's Advanta Dx SARS-CoV-2 RT-PCR Assay on its Biomark...

4 months ago - Benzinga

The company reported disappointing fourth-quarter results.

5 months ago - The Motley Fool

Fluidigm (FLDM) delivered earnings and revenue surprises of -225.00% and -11.26%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Fourth Quarter Total Revenue Increased 38 Percent to $44.6 million

5 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health i...

5 months ago - GlobeNewsWire

PLT and Fluidigm Collaborate on Submission to the National Medical Products Administration for a CyTOF Device Approved for Diagnostic Use in China PLT and Fluidigm Collaborate on Submission to the Natio...

5 months ago - GlobeNewsWire

On Wednesday, February 10, Fluidigm (NASDAQ:FLDM) will report its last quarter's earnings. Here is Benzinga's preview of the company's release.

5 months ago - Benzinga

Researchers Seek Insight into Development and Progression of Multisystem Inflammatory Syndrome in Children

5 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health i...

5 months ago - GlobeNewsWire

Fluidigm (FLDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

The company is now cleared to sell its saliva-based COVID-19 test in Europe.

6 months ago - The Motley Fool

Fluidigm (NASDAQ: FLDM) shares are trading higher Friday after the company announced it received the CE-IVD mark for its Advanta Dx SARS-CoV-2 RT-PCR Assay. Fluidigm manufactures life science tools focu...

Other stocks mentioned: SEEL, ADMP, BCRX
6 months ago - Benzinga

Fluidigm (FLDM) stock is soaring higher on Friday following an update for the company's saliva-based novel coronavirus test. The post FLDM Stock Alert: Why Fluidigm Shares Are Shooting Higher Today appe...

6 months ago - InvestorPlace

SOUTH SAN FRANCISCO, Calif., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health i...

6 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health i...

6 months ago - GlobeNewsWire

Study Highlighting IMC Application in Both Protein and RNA Detection Conducted by Researchers at Fluidigm C enter of Excellence for  Imaging Mass Cytometry at Georgetown Lombardi Comprehensive Cancer Ce...

6 months ago - GlobeNewsWire

Investors focused on tech growth stocks may want to consider the following businesses, as their quarterly revenue and net income have advanced strongly on a year-over-year basis.

Other stocks mentioned: IPHI, TENB
7 months ago - GuruFocus

SOUTH SAN FRANCISCO, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health i...

7 months ago - GlobeNewsWire

SAN DIEGO, Dec. 08, 2020 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain investors in NASDAQ: FLDM shares.

7 months ago - GlobeNewsWire

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Fluidigm (FLDM).

8 months ago - Zacks Investment Research

Fluidigm Assay is Among First Saliva-Based COVID-19 Tests Licensed for Use by Designated Labs in India Fluidigm Assay is Among First Saliva-Based COVID-19 Tests Licensed for Use by Designated Labs in India

8 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health i...

8 months ago - GlobeNewsWire

Los Angeles, California--(Newsfile Corp. - November 20, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Fluidigm Corpor...

8 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - November 20, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of ...

8 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - November 20, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Fluidigm Corporation ("Fluidigm" or "t...

8 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - November 19, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Fluidigm Corporation (NASDAQ: FLDM) alle...

8 months ago - Newsfile Corp

NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Fluidigm Corporation ("Fluidigm” or "the Company") (NASDAQ: FLDM) and ...

8 months ago - Business Wire

New York, New York--(Newsfile Corp. - November 19, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fluidigm Corporation (NASDAQ: FLDM) between February...

8 months ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - November 19, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Fluidigm Corpor...

8 months ago - Newsfile Corp

Weill Cornell Medicine Researchers Utilize Fluidigm Hyperion Imaging System to Identify a Phenotype of Immune Cell Activity Distinct from Other Lung Infections

8 months ago - GlobeNewsWire

LOS ANGELES, Nov. 18, 2020 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming November 20, 2020 deadline to file a lead plaintiff motion in the class action filed on b...

8 months ago - PRNewsWire

Los Angeles, California--(Newsfile Corp. - November 18, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Fluidigm Corpor...

8 months ago - Newsfile Corp

LOS ANGELES--(BUSINESS WIRE)---- $FLDM #classaction--The Law Offices of Frank R. Cruz reminds investors of the upcoming November 20, 2020 deadline to file a lead plaintiff motion in the class action fil...

8 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health i...

8 months ago - GlobeNewsWire

NEW YORK, Nov. 13, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fluidigm Corporation (NASDAQ: FLDM) between February 7, 2019 and Novemb...

8 months ago - PRNewsWire

New York, New York--(Newsfile Corp. - November 13, 2020) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a sec...

8 months ago - Newsfile Corp

NEW YORK, Nov. 10, 2020 /PRNewswire/ --Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action...

8 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health i...

8 months ago - GlobeNewsWire

Fluidigm Corporation (FLDM) CEO Chris Linthwaite on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

New York, New York--(Newsfile Corp. - November 6, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fluidigm Corporation (NASDAQ: FLDM) between February ...

8 months ago - Newsfile Corp

About FLDM

Fluidigm Corporation creates, manufactures, and markets technologies and life sciences tools worldwide. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, Hyperion tissue imager, and flow conductor; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow., as well as Maxpar direct immune profiling assays and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instrume... [Read more...]

Industry
Diagnostics & Research
IPO Date
Feb 10, 2011
CEO
Stephen Linthwaite
Employees
627
Stock Exchange
NASDAQ
Ticker Symbol
FLDM
Full Company Profile

Financial Performance

In 2020, Fluidigm's revenue was $138.14 million, an increase of 17.83% compared to the previous year's $117.24 million. Losses were -$53.02 million, -18.17% less than in 2019.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for Fluidigm stock is "Strong Buy." The 12-month stock price forecast is 9.33, which is an increase of 31.41% from the latest price.

Price Target
$9.33
(31.41% upside)
Analyst Consensus: Strong Buy